Kidney Cancer UK
Cabo+Nivo combo gets positive CHMP recommendation
Ipsen Receives Positive CHMP Opinion Recommending Cabometyx® in Combination With Opdivo® as First-line Treatment for Patients Living With Advanced Renal Cell Carcinoma... Read More
First US patients dosed with novel imaging radiopharmaceutical for RCC
The phase 3 ZIRCON trial is assessing TLX250-CDx as a noninvasive tool to identify clear cell renal cell carcinoma in patients with... Read More
Watch Again – #LWKC Webinar: Let’s talk about Work
We are pleased to present the edited highlights of our #LWKC Webinar ”Let’s Talk About Work’, a conversation on working while living... Read More
Watch again – #LWKC Webinar: Treating Small Kidney Tumours
We are pleased to be able to present the edited highlights of our #LWKC Webinar ‘Treating Small Kidney Tumours – An overview... Read More
Cabo+Tecentriq combo shows promise in advanced ccRCC
Treatment with Cabometyx (cabozantinib) in combination with Tecentriq (atezolizumab) demonstrated promising clinical activity in patients with advanced clear cell renal cell carcinoma... Read More
SMC approves combination therapy for patients in Scotland
Kidney Cancer Scotland add their voice to those praising the Scottish Medicine Consortium’s (SMC) approval of the therapy Keytruda (pembrolizumab) in combination... Read More
NICE rejects pembro+axitinib therapy for aRCC
Kidney cancer community strongly disagrees with NICE decision not to approve pembrolizumab with axitinib therapy Kidney Cancer UK, the UK’s largest kidney... Read More
Serum reported to be a prognostic marker for RCC
There has been no clinically useful diagnostic or prognostic biomarker for renal cell carcinoma (RCC). Serum γ-glutamyltransferase (GGT) activity has been reported... Read More
Study shows Rise in Wilms Tumour
A study points to a rise in renal carcinomas in children, known as ‘Wilms Tumour’. Wilms tumour remains the most common type... Read More
RCC combo approved on CDF
The UK’s first as breakthrough kidney cancer combination treatment has been approved for immediate use through the Cancer Drugs Fund (CDF) in... Read More
Cabo/atezo phase 3 combo RCC trial launched
The phase 3 CONTACT-03 trial is exploring the combination of the multikinase inhibitor and immunotherapy agent in patients with renal cell carcinoma... Read More
Biomarker combo may help predict mRCC immuno response
When deciding on the best course of treatment for patients with metastatic renal cell carcinoma (mRCC), it’s difficult for oncologists to know... Read More
Leeds cancer nurse wins inaugural Melinda Whale Memorial Award 2019
A Leeds nurse was the first to receive a high-profile award recognising her dedication, care and unwavering support for kidney cancer patients.... Read More
Plans to ease guidance for over 2 million shielding
Advisory guidance to be eased for 2.2 million clinically extremely vulnerable people across England, as virus infection rates continue to fall From... Read More
Analysis findings from KEYNOTE-427 ccRCC trial
In an interview with Targeted Oncology, Scott Tykodi, MD, PhD, a physician with the Seattle Cancer Care Alliance, and associate professor in... Read More
Researchers underscore efficacy of Pembrolizumab+Axitinib in treating advanced Rcc
ASCO 2020: Researchers underscore efficacy of pembrolizumab plus axitinib in treating advanced renal cell carcinoma Researchers at Fox Chase Cancer Center, along... Read More
How GP’s should support ‘Shielded’ Patients
Patients who are most at risk of severe complications from COVID-19 have been asked to ‘shield’ themselves. This means that they should... Read More
Cancer patients to get surgery in ‘Covid-free’ hubs
Thousands of cancer patients will be operated on at new “Covid-free” hubs in hospitals across England as the NHS consolidates urgent surgery in fewer... Read More
Seek help if you show cancer symptoms, urge NHS
NHS WARNING TO SEEK HELP FOR CANCER SYMPTOMS, AS HALF OF PUBLIC REPORT CONCERNS WITH GETTING CHECKED England’s top cancer doctor has... Read More
Pexa-Vec with immunotherapy reduced tumor in 75% of RCC patients
San Francisco based SillaJen Biotherapeutics said a combination of its oncolytic viral therapy Pexa-Vec (JX-594) with immune check inhibitor Libtayo (ingredient: cemiplimab)... Read More
Covid-19 vulnerable patient list balloons by 500,000
The number of patients asked to “shield” themselves from coronavirus is expected to reach two million by the end of the month,... Read More
Cryoablation Safe, Efficacious for Small Renal Tumors
Image-guided percutaneous cryoablation is a safe and efficacious treatment for selected small renal cell carcinoma (RRC) tumors, new findings published in the... Read More
Drug combo hits targets in first-line RCC trial
Bristol Myers Squibb and Exelixis have announced that a late-stage study testing a combination of Opdivo (nivolumab) and Cabometyx (cabozantinib) has hit... Read More
Create covid-free hubs for cancer patients, Trusts told
Trusts have been told to urgently reconfigure surgical cancer services into covid-free hubs to minimise the number of procedures being postponed. In... Read More
